Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + dexamethasone sodium phosphate + bupivacaine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Parenteral, Intraarticular, Intralesional, Intramuscular
01
Overview
A fixed combination of two corticosteroids, triamcinolone acetonide and dexamethasone sodium phosphate, with the local anesthetic bupivacaine. The corticosteroid components act primarily through agonism of the glucocorticoid receptor to suppress inflammatory gene transcription, reduce leukocyte trafficking, and decrease local edema and pain, while bupivacaine blocks voltage-gated sodium channels to produce prolonged local anesthesia. Based on the provided context, this appears to represent a compounded or locally administered steroid-anesthetic injection used for anti-inflammatory and analgesic purposes rather than a distinct widely branded proprietary asset.
- Other names
- triamcinolone acetonide + dexamethasone sodium phosphate + bupivacaine
02
Targets
NaV alpha (Voltage-gated sodium channel alpha subunit family)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone acetonide + dexamethasone sodium phosphate + bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + dexamethasone sodium phosphate + bupivacaine.